AZN.LSE
AstraZeneca PLC
117,00£
-1,2 %
zum Vortag
Schlusskurs · Stand: 12. Aug 2026
Abschluss
GuV
AstraZeneca PLC (AZN.LSE) im Zahlenüberblick: Gewinn- und Verlustrechnung, Bilanz und Cashflow, wahlweise je Jahr oder Quartal. Im jüngsten Berichtszeitraum (2025) lag „Umsatz" bei 58.739 Millionen USD. Zeilen lassen sich per Häkchen als Diagramm vergleichen.
Alle Werte in Millionen USD.
Zeilen ankreuzen und als Diagramm vergleichen (bis zu 4)
| Position | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.184 | 8.586 | 9.146 | 18.436 | 18.116 | 23.571 | 17.850 | 18.849 | 22.480 | 22.695 | 28.161 | 29.347 | 30.659 | 33.803 | 33.324 | 32.472 | 28.350 | 26.737 | 25.886 | 23.925 | 20.922 | 23.451 | 20.985 | 24.499 | 29.270 | 37.107 | 44.253 | 46.583 | 52.944 | 58.739 | |
| – | – | – | – | 4.509 | 3.584 | 4.522 | 4.469 | 5.737 | 5.248 | 6.202 | 6.511 | 6.642 | 6.595 | 6.838 | 6.555 | 6.306 | 6.668 | 7.233 | 5.897 | 5.067 | 6.072 | 5.922 | 6.774 | 7.608 | 14.508 | 16.213 | 12.135 | 13.246 | 10.633 | |
| 9.184 | 8.586 | 9.146 | 18.436 | 18.116 | 23.571 | 13.328 | 14.380 | 16.743 | 17.447 | 21.959 | 22.836 | 24.017 | 27.208 | 26.485 | 25.917 | 22.044 | 20.069 | 18.653 | 18.028 | 15.855 | 17.379 | 15.063 | 17.725 | 21.662 | 22.599 | 28.040 | 34.448 | 39.698 | 48.106 | |
| 1.031 | 1.079 | 1.175 | 2.922 | 2.895 | 3.965 | 3.071 | 3.451 | 3.638 | 3.202 | 4.132 | 5.052 | 4.714 | 4.370 | 4.100 | 4.356 | 4.298 | 4.421 | 4.818 | 5.425 | 5.122 | 5.650 | 5.003 | 5.345 | 6.464 | 8.383 | 9.618 | 10.519 | 11.963 | 14.232 | |
| – | – | – | – | 5.977 | 5.549 | 6.001 | 6.856 | 8.268 | 8.906 | 9.322 | 10.612 | 11.204 | 11.332 | 10.445 | 11.161 | 9.839 | 12.206 | 13.000 | 10.685 | 9.413 | 10.233 | 10.362 | 11.099 | 11.693 | 95 | 18.955 | 17.683 | 19.669 | 19.933 | |
| 7.316 | 6.774 | 7.174 | 13.623 | 13.643 | 17.577 | 8.969 | 10.269 | 12.166 | 11.383 | 13.702 | 14.564 | 14.357 | 15.343 | 13.835 | 14.168 | 13.070 | 13.668 | 15.044 | 14.561 | 12.614 | 13.755 | 13.319 | 14.905 | 16.693 | 19.790 | 22.991 | 24.878 | 27.176 | 34.363 | |
| 1.786 | 1.790 | 1.821 | 2.674 | 3.665 | 5.656 | 4.358 | 4.111 | 4.577 | 6.064 | 8.256 | 8.272 | 9.660 | 11.865 | 12.651 | 11.749 | 8.974 | 6.402 | 3.609 | 3.468 | 3.241 | 3.623 | 1.744 | 2.820 | 4.970 | 2.809 | 5.049 | 9.570 | 12.522 | 13.743 | |
| 110 | 101 | 106 | 167 | 131 | 135 | 0,0 | 0,0 | 48 | 58 | 77 | 518 | 693 | 577 | 480 | 419 | 432 | 429 | 408 | 380 | 561 | 693 | 704 | 776 | 781 | 759 | 887 | 1.151 | 1.362 | 1.694 | |
| 1.670 | 1.787 | 1.735 | 1.958 | 3.851 | 5.832 | 4.039 | 4.202 | 5.082 | 6.318 | 9.087 | 7.926 | 8.422 | 11.136 | 10.995 | 11.955 | 7.749 | 3.397 | 1.215 | 2.972 | 3.231 | 2.325 | 1.893 | 1.555 | 4.154 | -260 | 2.495 | 7.015 | 8.510 | 12.402 | |
| 548 | 570 | 548 | 815 | 1.299 | 1.659 | 1.178 | 1.143 | 1.218 | 1.841 | 2.638 | 2.339 | 2.475 | 3.362 | 2.901 | 2.273 | 1.395 | 724 | 11 | 235 | 133 | -669 | -54 | 323 | 819 | -373 | -790 | 954 | 1.616 | 2.169 | |
| 1.101 | 1.207 | 1.185 | 1.142 | 2.541 | 4.156 | 2.837 | 3.036 | 3.844 | 4.459 | 6.428 | 5.555 | 5.919 | 7.750 | 8.066 | 9.651 | 6.324 | 2.658 | 1.202 | 2.735 | 3.183 | 3.133 | 2.047 | 1.341 | 3.390 | 110 | 3.281 | 6.055 | 6.888 | 10.225 | |
| 2.151 | 2.245 | 3.248 | 4.499 | 4.911 | 5.016 | 4.966 | 5.300 | 6.418 | 7.548 | 10.520 | 10.062 | 11.045 | 13.384 | 13.364 | 14.304 | 10.531 | 6.619 | 4.710 | 5.958 | 5.923 | 5.636 | 5.345 | 5.243 | 8.035 | 4.585 | 8.630 | 13.196 | 14.858 | 19.829 |
Datenstand: 12. August 2026 · Quelle: Fundamentaldaten & SEC-Berichte (Geschäfts- und Quartalsberichte, 10-K/10-Q)
Hinweis: reine Faktenanalyse, keine Anlageberatung und keine Aufforderung zum Kauf oder Verkauf. Angaben ohne Gewähr.